Mainland China’s human vaccine market amounted to 21.6 billion yuan in 2017, or 11.5 per cent of the global total. Photo: AP Mainland China’s human vaccine market amounted to 21.6 billion yuan in 2017, or 11.5 per cent of the global total. Photo: AP
Mainland China’s human vaccine market amounted to 21.6 billion yuan in 2017, or 11.5 per cent of the global total. Photo: AP
Health in China

Meet Wuxi Biologics, the contract drugs maker that believes it can help cure China’s scandal-hit vaccine market

  • Wuxi Biologics is in talks with three separate vaccine developers to manufacture their products in China
  • ‘We already have a globally accepted quality assurance system … we can play a leading role in elevating vaccine standards,’ says chief executive

Topic |   Health in China
Mainland China’s human vaccine market amounted to 21.6 billion yuan in 2017, or 11.5 per cent of the global total. Photo: AP Mainland China’s human vaccine market amounted to 21.6 billion yuan in 2017, or 11.5 per cent of the global total. Photo: AP
Mainland China’s human vaccine market amounted to 21.6 billion yuan in 2017, or 11.5 per cent of the global total. Photo: AP
READ FULL ARTICLE